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Key points 
Question: Among patients with relapsing-remitting multiple sclerosis (RRMS), what is the association 
between disease-modifying therapies (DMTs) and the risk of conversion to secondary progressive 
multiple sclerosis (SPMS)?  
 
Findings: In this cohort study involving 1,555 patients with RRMS, initial treatment with fingolimod, 
natalizumab or alemtuzumab was associated with a lower risk of conversion to SPMS compared with 
ß-interferon or glatiramer acetate (hazard ratio 0.66). 
 
Meaning: These findings, considered along with the risks associated with these therapies, may help 
inform decisions regarding DMT selection for patients with RRMS.  
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Abstract 
Importance: Within two decades of onset, 80% of untreated patients with relapsing-remitting 
multiple sclerosis (RRMS) convert to a phase of irreversible disability accrual termed secondary 
progressive (SP) MS. The association between disease-modifying treatments (DMTs) on conversion 
to SPMS has rarely been studied and - to the best of our knowledge - never using a validated 
definition.  
Objective: To determine the association between the use of DMTs, the type of initial DMT, and the 
timing of DMT escalation with the risk of conversion to SPMS using a validated definition of SPMS.  
Design, Setting and Participants:  Cohort study with prospective data collection from 68 neurology 
centers in 21 countries examining patients with RRMS commencing DMTs (or monitoring if 
untreated) between 1988-2012 with minimum 4 years’ follow-up.  
Exposure: The use, type and timing of the following DMTs: ß-interferon or glatiramer acetate (ß-
IFN|GA), fingolimod, natalizumab or alemtuzumab.  
Main outcomes and measures: Conversion to SPMS using a validated definition.  
Results: Following propensity-score matching for baseline demographics, 1,555 patients were 
included (1,123 female, mean baseline age 35 (standard deviation 10) years, last visit date 14th 
February 2017. Compared to matched untreated patients, a lower hazard of conversion to SPMS was 
seen in patients initially treated with ß-IFN|GA (hazard ratio (HR) 0.71 (95% CI 0.61−0.81), p<0.001, 
5-year absolute risk (AR) 27% (58/213) vs 12% (49/407) respectively, median follow-up 7.6 (IQR 5.8-
9.6) years), fingolimod (HR 0.37 (95% CI 0.22−0.62), p<0.001, 5-year AR 32% (56/174) vs 7% (6/85) 
respectively, follow-up 4.5 (IQR 4.3-5.1) years), natalizumab (HR 0.61 (95% CI 0.43−0.86), p=0.005, 5-
year AR 38% (62/164) vs 19% (16/82) respectively, follow-up 4.9 (IQR 4.4-5.8) years) and 
alemtuzumab (HR 0.52 (95%CI 0.32−0.85), p=0.009, 5-year AR 25% (23/92) vs 10% (4/44) 
respectively, follow-up 7.4 (IQR 6.0-8.6) years). Initial treatment with fingolimod, alemtuzumab or 
natalizumab was associated with a lower risk of conversion than initial treatment with ß-IFN|GA (HR 
0.66 (95% CI 0.44-0.99), p=0.046, 5-year AR 7% (16/235) vs 12% (46/380) respectively, median 
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follow-up 5.8 (IQR 4.7-8.0) years). The probability of conversion was lower when ß-IFN|GA was 
started within 5 years of disease onset versus later commencement (HR 0.77 (95%CI 0.61-0.98), 
p=0.03, 5-year AR 3% (4/120) vs 6% (2/38) respectively median follow-up 13.4 (IQR 11-18.1) years); 
and when patients on ß-IFN|GA were escalated to fingolimod, alemtuzumab or natalizumab within 5 
years of disease onset compared to later escalation (HR 0.76 (95% CI 0.66-0.88), p<0.001, 5-year AR 
8% (25/307) vs 14% (46/331) respectively, median follow-up 5.3 (IQR 4.6-6.1) years).  
Conclusions and Relevance: Among patients with RRMS, initial treatment with fingolimod, 
natalizumab or alemtuzumab was associated with a lower risk of conversion to SPMS compared to 
initial treatment with ß-IFN|GA over a median 5.8 years of follow-up.  These findings, considered 
along with these therapies’ risks, may help inform decisions about DMT selection.  
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Introduction 
Multiple sclerosis (MS) is amongst the most common causes of disability in young adults. Eighty five 
percent of patients present with the relapsing-remitting form (RRMS) for which several 
immunomodulatory disease-modifying therapies (DMTs) reduce relapse rates and disability 
accumulation.1-5 Within two decades of onset, 80% of untreated patients with RRMS convert to a 
phase of sustained disability accrual termed secondary progressive multiple sclerosis (SPMS).6 This 
phase is responsible for much of the disease’s negative physical, psychological and societal effects. 
Until recently no rigorous definition of SPMS existed, leading to varying criteria and contradictory 
results from one randomised trial extension7 and seven observational studies8-14 that predominantly 
examined the effects of ß-interferon or glatiramer acetate (ß-IFN|GA) on conversion to SPMS.  
Using a recently-published validated definition of SPMS,15 the rate of conversion to SPMS was 
examined between (i) different DMTs and an untreated cohort, (ii) fingolimod, alemtuzumab or 
natalizumab (F|A|N) versus ß-IFN|GA, and (iii) treatment commencement or escalation within 
versus after 5 years of disease onset.  
 
Methods 
Ethical approval was granted by the Melbourne Health Human Research Ethics Committee and by 
each site’s institutional review board. All enrolled patients provided written or verbal consent, as per 
local regulations. 
 
Patients and inclusion criteria 
This international observational cohort study utilised prospectively-collected clinical data from three 
sources (all accessed in February 2017). Untreated patients were selected from the 
neuroinflammatory service database at the University Hospital of Wales, a tertiary referral centre in 
South-East Wales. Clinical data was initially collected as part of a cross-sectional study16 then 
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through annual or semi-annual appointments. Treated patients were identified from MSBase, an 
observational cohort study collecting real-world data from patients with multiple sclerosis across 
105 centers in 29 countries.17 Additional alemtuzumab-treated patients were identified from five 
European non-MSBase centers using alemtuzumab before it was licensed18 (Bristol, Cardiff, Swansea, 
Dublin and Dresden). Within MSBase, ß-IFN|GA, fingolimod and natalizumab had sufficient patient 
numbers with more than 4-years on-treatment follow-up (while teriflunomide and dimethyl-
fumarate did not, so they were not included). The 4-year minimum follow-up period represented the 
longest follow-up period without excluding the majority of patients in MSBase treated with 
natalizumab or fingolimod. Data were subject to rigorous data-quality procedures (eTable S1). 
For inclusion, patients needed to be classified as RRMS (clinically definite MS19) at baseline, required 
the complete MSBase minimum dataset (sex, date of birth, date of clinical onset and dates of 
relapses),20 at least one Expanded Disability Status Scale21 (EDSS) score no more than 6 months 
before baseline and at least two EDSS scores after baseline (one to detect disability progression and 
another to confirm the increase later (see definition below)). Patients stopping their initial therapy 
within 6 months were excluded (as some drugs require 6 months to exert their effect22). The 
untreated cohort received no DMTs, even briefly. DMT dose, frequency and timing followed 
published protocols18,23: alemtuzumab (12–24 mg intravenous once per day for 5 days [cycle 1] or for 
3 days [cycle 2 or more]); ß-IFN (30-250 μg subcutaneous or intramuscular injections administered 
between every other day to every other week); glatiramer acetate (20 mg subcutaneous injection 
once per day); fingolimod (0·5 mg oral once per day), and natalizumab (300 mg intravenously every 
4 weeks). Given its administration schedule, quantifying the duration of alemtuzumab treatment 
effectiveness is challenging: first, the published period of reduced CD4 lymphocyte count (35 
months/cycle24) was used, and then a sensitivity analysis using the median period to re-treatment (7 
years25) was performed. If patients received multiple DMTs, the first was used as the DMT under 
study (except when comparing early versus late escalation from ß-IFN|GA to F|A|N). Patients 
subsequently receiving different DMTs were excluded from analyses of single drugs versus untreated 
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patients but were included in all other analyses. Patients receiving therapies at any time during the 
study period that were unlicensed were excluded (mitoxantrone, cladribine, rituximab, ocrelizumab, 
siponimod or autologous stem-cell transplantation). Although ocrelizumab and cladribine have 
subsequently been licensed, there were insufficient numbers meeting the minimum 4 years’ clinical 
follow-up criterion within MSBase to examine individually. 
No licensed therapies have shown greater reduction in relapse rates than natalizumab or 
alemtuzumab.18 Patients receiving natalizumab or alemtuzumab who experienced relapses or 
disability-progression in this study were therefore already at the therapeutic ceiling of treatment. 
This was replicated for patients receiving ß-IFN|GA (in all analyses) by restricting inclusion to 
patients treated and followed-up before fingolimod, alemtuzumab or natalizumab became available, 
preventing the exclusion of patients who might have been prescribed these more potent therapies 
as first-line or escalation therapy during follow-up, and thereby preventing selection bias towards 
milder disease among the ß-IFN|GA group. (During this period, mitoxantrone was occasionally 
employed as escalation therapy for particularly aggressive disease: to ensure the ß-IFN|GA cohorts 
were not biased towards milder disease, sensitivity analyses including these patients were 
performed). Consistent with previous work,18 patients participating in clinical trials were excluded as 
their trial treatment assignation was not documented within MSBase, and trial EDSS frequencies 
often differ to clinical practice. Patients with previous stem cell transplantation were also excluded.  
 
Study design 
To examine whether individual DMTs were associated with delayed or reduced conversion to SPMS, 
matching and analyses were repeated four times comparing untreated patients to those receiving 
initial treatment with (a) ß-IFN|GA, (b) fingolimod, (c) natalizumab, or (d) alemtuzumab. In these 
analyses, the date of DMT commencement acted as the baseline date for treated patients. For 
untreated patients, the baseline date was the visit date when clinical and demographic parameters 
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(calculated at each visit and quantified using the propensity score) most closely matched the 
corresponding baseline values of individual treated patients. 
Fingolimod,4 alemtuzumab5 and natalizumab26 (F|A|N) confer greater reductions in relapse rate 
than ß-IFN|GA. To examine whether they are associated with different effects on conversion to 
SPMS, patients receiving F|A|N as their initial DMT were matched and compared to patients initially 
treated with ß-IFN|GA.  
To examine the association between timing of DMT commencement and conversion to SPMS, 
patients initially treated with ß-IFN|GA within 5 years of disease onset were matched and compared 
with those initially treated after 5 years. For patients treated within 5 years, the baseline was set at 
DMT commencement. For all patients treated after 5 years, the baseline was set at a visit within 5 
years of symptom-onset, before therapy began, incorporating the period from baseline to treatment 
initiation into the follow-up. The date of this visit was identified by extracting the matching variables 
at each eligible visit within 5 years of symptom-onset, then using a matching process to identify 
when these variables most closely matched those of a patient treated within 5 years.  By handling 
treatment exposure as a time-dependent variable, the analyses accounted for immortal time bias, 
including the untreated time from baseline to treatment initiation in the group treated after 5 years. 
This technique was repeated when comparing escalation from ß-IFN|GA to F|A|N within or after 5 
years of disease onset. 
 
Outcome 
The outcome in all analyses was conversion to SPMS based on an objective definition15 without 
functional scores: patients required an EDSS increase (if the EDSS score was 5.5 or less, an increase 
of 1 point was required; if the EDSS score was over 5.5 an increase of 0.5 points was required). This 
EDSS increase had to (i) occur in the absence of a relapse, (ii) be confirmed at subsequent 
appointments over at least 3 months; and (iii) the resultant EDSS score had to be 4 or more.15 
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Matching 
Using the MatchIt package27 (v2.4-22) the propensity of treatment was estimated using a 
multivariable logistic regression model using baseline age, sex, annualised-relapse rate in the year 
prior to baseline, EDSS score and disease duration. To minimise the difference in proportions of time 
on therapy during follow-up in the ß-IFN|GA versus F|A|N analysis, patients were additionally 
matched on the proportion of time on therapy during the median follow-up period (first 5.8 years). 
Patients in the early versus late escalation from ß-IFN|GA to F|A|N analysis were also matched on 
disease duration at the time of starting ß-IFN|GA plus the individual therapy they were escalated to. 
To increase matching precision,18,28 patients were matched in a variable matching ratio (10:1 to 1:1) 
by nearest neighbour matching using the optimal caliper (0.1 standard deviations (SD) of the 
propensity score).29-31 Where treatment initiation was not used as the baseline (the late group in the 
early versus late ß-IFN|GA and escalation analyses; and the untreated group in all untreated 
analyses), any visit could serve as baseline (to optimise matching). A single patient could therefore 
be used multiple times in one analysis and across analyses. To account for this, replacement was 
permitted in these matching models. All subsequent models were weighted to account for the 
variable matching ratio (see below). Each patient’s follow-up was censored to the shortest of the 
two follow-up times from each set, resulting in identical follow-up durations between groups. Sets 
where either patient subsequently had less than two EDSS scores following baseline were excluded. 
 
Statistical analysis 
All analyses were performed using the survival package (v3.3.1) in R. Setwise weighted conditional 
proportional hazards models (Cox) clustered for matched patient sets examined the proportions of 
patients free from conversion to SPMS. All models were adjusted for EDSS frequency plus any 
variables showing residual imbalance following matching (as denoted by a standardised difference 
(quantified by Cohen’s d value) ≥ 0.232 (which indicates less than 92% overlap between the groups)). 
The weights were calculated as the inverse of the number of times a patient was included in an 
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analysis to account for the variable matching ratio. The models comparing (i) ß-IFN|GA with F|A|N, 
(ii) early versus late ß-IFN|GA and (iii) early versus late escalation from ß-IFN|GA to F|A|N were also 
adjusted for the proportion of time on therapy during the entire post-baseline setwise-censored 
follow-up. The Schoenfeld’s global test33 was used to detect violation of the proportional hazards 
assumption; when violated, Weibull accelerated failure time regression models were used. To 
estimate the conditional hazard ratio, robust estimation of variance based on the Huber sandwich 
estimator was used. The Efron approximation was used to resolve tied survival times. Graphs were 
censored at the latest point that each group contained at least 10 patients or less than 10% of the 
original group, whichever came first. The percentage of patients that had converted to SPMS are 
presented at 5 years and the last year before censor in the text. Two-sided significance testing was 
used. Results were considered significant at the p<0.05 level. Because there was no adjustment for 
multiple comparisons, secondary analyses should be interpreted as exploratory. 
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Results 
44,217 patients with multiple sclerosis (1,091 from the Welsh untreated cohort; 43,048 from 
MSBase and 78 alemtuzumab-treated patients from non-MSBase centers) were assessed for 
eligibility (Figure 1). To avoid informed censoring bias, the ß-IFN|GA groups were limited to those 
treated and followed-up before F|A|N became available for escalation (baseline year 1996-1998 
(Table 1)). Following exclusion of ineligible patients (Figure 1), the matching process then matched 
1,555 patients from 68 centers in 21 countries (eTable S3): 230 from the Welsh untreated cohort; 
1,272 from MSBase and 53 alemtuzumab-treated patients from non-MSBase centers (Table 1, 
eTables S3-4). Matching coefficients and post-SPMS EDSS scores are shown in eTables S5-6 
respectively. The assumption of proportionality was not met in 6/9 analyses (requiring Weibull 
accelerated failure time regression models). 
Compared with no treatment, treatment with each included therapy was associated with a 
significantly lower probability of converting to SPMS. For patients initially treated with ß-IFN|GA 
(n=407), the hazard ratio (HR) was 0.71 (95% confidence interval (CI) 0.61−0.81), p<0.001 in 
comparison to untreated patients (n=213); median censored follow-up 7.6 (IQR 5.8-9.6) years); at 5 
years 12% vs 27% respectively had converted, while at 11 years 47% vs 57% had converted (Figure 
2A). Fewer patients initially treated with fingolimod (n=85) converted compared to untreated 
patients (n=174) (HR 0.37 (95% CI 0.22−0.62), p<0.001; median censored follow-up 4.5 (IQR 4.3-5.1) 
years): at 5 years 7% vs 32% respectively had converted, while at 6 years 7% vs 39% had converted 
(Figure 2B). Conversion to SPMS was also significantly lower for patients initially treated with 
natalizumab (n=82) compared to untreated patients (n=164) (HR 0.61 (95% CI 0.43−0.86), p=0.005; 
median censored follow-up 4.9 (IQR 4.4-5.8) years): at 5 years 19% vs 38% respectively had 
converted, while at 6 years 34% vs 48% had converted (Figure 2C). The hazard ratio for converting to 
SPMS was significantly lower for patients initially treated with alemtuzumab (n=44) compared to 
untreated patients (n=92) (0.52 (95%CI 0.32−0.85), p=0.009; median censored follow-up 7.4 (IQR 
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6.0-8.6) years): at 5 years 10% vs 25% respectively had converted, while at 8 years 21% vs 41% had 
converted (Table 1, Figure 2D).  
The probability of converting to SPMS was significantly lower for patients initially receiving ß-IFN|GA 
within 5 years of disease onset (n=120) compared to matched patients treated with ß-IFN|GA later 
(n=38) (HR 0.77 (95%CI 0.61-0.98), p=0.03), median censored follow-up 13.4 (IQR 11-18.1) years. 
Five years after baseline 3% vs 6%, respectively, had converted to SPMS, while at 17 years 29% vs 
47% had converted (Figure 3A). Including patients escalated to mitoxantrone did not materially alter 
the results (HR 0.82 (95%CI 0.67-1.00), p=0.05). The probability of converting to SPMS was 
significantly lower when initial treatment with ß-IFN|GA was commenced within 5 years of disease 
onset (n=164) compared to untreated patients (n=104) (HR 0.26 (95%CI 0.15-0.45), p<0.001) with 
the difference increasing proportionally throughout the 11 years of follow-up (corresponding to 14 
years disease duration (Figure 3B)). In contrast, the significantly lower probability of conversion 
following initial treatment with ß-IFN|GA commencing 5-10 years after disease onset (n=95) 
compared to untreated patients (n=158, HR 0.67 (95%CI 0.51-0.87), p=0.003) waned after 5 years of 
treatment (disease duration 11.8 years) and disappeared at 7.8 years (disease duration 14.6 years, 
Figure 3C)). The probability of converting to SPMS was significantly lower for patients escalated from 
ß-IFN|GA to F|A|N within 5 years of disease onset (n=307) compared to matched patients escalated 
later (n=331, HR 0.76 (95%CI 0.66-0.88), p<0.001; median censored follow-up 5.3 (IQR 4.6-6.1) 
years): at 5 years, 8% vs 14% respectively had converted while at 7 years, 14% vs 28% had converted 
(Figure 3D). This difference persisted when the alternative (7-year) definition of alemtuzumab 
treatment duration was employed in a sensitivity analysis (HR 0.78 (95%CI 0.67-0.91), p=0.001). 
Patients initially receiving F|A|N (n=235) had a significantly lower risk of conversion to SPMS than 
matched patients initially receiving ß-IFN|GA (n=380) (HR 0.66 (95% CI 0.44-0.99), p=0.046; median 
censored follow-up 5.8 (IQR 4.7-8.0) years). At 5 years, 7% vs 12% respectively had converted, while 
at 9 years, 16% vs 27% respectively had converted (Figure 4). This persisted in sensitivity analyses 
when the alternative (7-year) definition of alemtuzumab treatment duration was used (HR 0.60 
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(95%CI 0.39-0.90), p=0.01); and when patients in the ß-IFN|GA group escalated to mitoxantrone 
were included (HR 0.88 (95%CI 0.84-0.91), p<0.001).  
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Discussion 
In this observational cohort study that used prospectively-collected clinical data, initial treatment 
with fingolimod, alemtuzumab or natalizumab (F|A|N) was associated with a significantly lower risk 
of conversion to SPMS compared to initial treatment with ß-IFN|GA. The risk of conversion was 
significantly lower for early compared to late treatment: either in the case of starting ß-IFN|GA 
within 5 years of disease onset versus later commencement, or when escalating from ß-IFN|GA to 
F|A|N within 5 years of disease onset versus later escalation.  
These results suggest that initial treatment with ß-IFN|GA is associated with reduced conversion to 
SPMS compared to untreated patients. There is no consensus in the literature. Intention-to-treat 
analysis of the study conducted by the IFN Multiple Sclerosis Study Group found no difference in 
conversion rates between interferon and placebo 16 years later, though many placebo-treated 
patients subsequently received DMTs.7 Six of seven observational studies reported favourable 
associations between ß-IFN|GA and SPMS conversion, both individually8-13 and in a meta-analysis.34 
The remaining observational study from British Columbia – the only one to circumvent immortal 
time bias35 through treating interferon exposure as a time-dependent variable (ensuring time before 
interferon treatment contributed to the untreated follow-up time) – found no relationship between 
interferon exposure and SPMS conversion.14 These observational studies – all published before an 
objective SPMS definition became available15 – have highly heterogeneous methods including 
variable (or inaccessible) SPMS definitions, inconsistent exclusion of relapse-related disability-
increases; and variable strategies for mitigating indication bias (arising from non-random treatment 
exposure), attrition bias (reflecting between-group differences in follow-up duration), detection bias 
(from differing EDSS frequency during follow-up) and immortal-time bias.8-14 In observational study 
designs, propensity score-based estimators better reflect true differences than nonexperimental 
estimators, such as multivariable regression or latent variable selection models, given that an 
overlap exists between the compared groups.36 In this analysis, matching with a caliper was 
employed, which is more robust in scenarios with restricted sample size and strong treatment-
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selection processes than unrestricted propensity score-based methods such as inverse probability of 
treatment weighting or optimal full matching.30,31 All models were adjusted for EDSS frequency to 
mitigate detection bias and setwise censoring of follow-up duration was used to mitigate attrition 
bias. To address the issue of immortal-time bias35 disease-modifying therapy was treated as a time-
dependent variable. The risk of SPMS conversion increases with disease duration,6 so it should be 
considered in evaluations of SPMS conversion rates in different treatment scenarios (Table 1, Figure 
2). For instance, subgroups with longer disease duration at baseline (e.g. here natalizumab) are 
expected to be associated with a relatively greater SPMS conversion rate than those with shorter 
disease duration at baseline (e.g. here alemtuzumab or fingolimod).  
 
Limitations 
This study has several limitations. First, given its observational design, the study is unable to ascribe 
causality and cannot distinguish between prevention and delay of conversion to SPMS. The longest 
comparison however showed a favourable association of early (versus later) ß-IFN|GA, enduring to 
the end of follow-up 17 years after baseline (median disease duration 20 years; Figure 3A). Second, 
the absence of EDSS functional score subcomponents precluded using the SPMS definition with the 
highest combination of sensitivity, specificity and accuracy; the definition used in this study, 
requiring total EDSS only, has previously been shown to be associated with a 1% loss of accuracy and 
6% reduction in sensitivity.15  Third, the differing baseline demographics of each DMT cohort (Table 
1) required differing matched untreated cohorts with differing follow-up durations; their relative 
therapeutic effects should therefore not be compared between analyses (Figures 2A-D). A particular 
problem with the fingolimod/untreated comparison was the inability to eliminate informed 
censoring bias because fingolimod-treated patients subsequently escalated to monoclonal antibody 
treatment (due to on-treatment disease activity) were excluded (Figure 2B). Such informed 
censoring does not affect the comparison between untreated patients and monoclonal antibodies 
(as patients cannot be escalated from these highly-effective therapies18) nor the untreated 
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comparisons with ß-IFN|GA (where the inclusion criteria ensured more potent therapies were not 
generally available during the studied epoch). Fourth, the ß-IFN|GA cohorts therefore came from an 
earlier period, leading to 10-11 years median difference in the baseline dates of the ß-IFN|GA versus 
untreated analyses, and 13 years median difference in the ß-IFN|GA versus F|A|N analysis. It is 
possible that unmeasured changes in care between time epochs - more specialist nurses, better 
symptomatic management, lower thresholds for escalating therapy for example - may have 
contributed to differences in SPMS conversion rates in these particular analyses.  However, all other 
analyses (with contemporaneous groups (≤5 years difference, Table 1)) also support early and 
aggressive DMT use. The ability to match contemporaneous untreated patients to those 
commencing F|A|N (Table 1) took advantage of the United Kingdom’s lower DMT uptake rates. The 
generalisability of the untreated group to other geographic regions cannot be guaranteed. Fifth, a 
large number of patients were excluded due to ineligibility (Figure 1). At least 65 patients were 
excluded through stopping their DMT within 6 months due to inefficacy (Figure 1). Though a modest 
number, their exclusion may have biased the remaining patients presented for matching towards a 
relatively milder disease. Those excluded due to missing data were slightly older with higher baseline 
EDSS scores (eTable S7). While the exclusion criteria have made the results more robust, the 
resultant unmatched cohorts are, by definition, unrepresentative of the whole unfiltered cohort. 
Despite the stringent matching criteria 63-97% of treated eligible patients were successfully 
matched, and beyond lower baseline relapse rates, the matched cohorts (Table 1) are similar to 
those in the original placebo-controlled phase III trials of these therapies.1-3  Sixth, some factors were 
unavailable across all cohorts (for example smoking status; lesion number or brain volume on MRI; 
drug adherence; or the presence of oligoclonal bands in cerebrospinal fluid), precluding their 
inclusion in matching models. If these variables differed systematically between the compared 
groups, and are associated with the risk of SPMS conversion, then they might have acted as 
confounders. Through the use of an objective SPMS definition, any positive bias of outcomes by the 
clinician instigating the intervention or escalation should have been mitigated.  Seventh, the 
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assessment of disability (and therefore SPMS conversion) relied on the EDSS. Although the most 
widely-used disability measure, it has high inter-rater variability at lower scores, limited sensitivity to 
cognitive impairment and – at scores over 3.5 – is largely determined by ambulation.38 To mitigate 
inter-rater variability, this published definition of SPMS requires EDSS step 4 attainment and 
confirmation of EDSS increases on two occasions, at least 3 months apart. Eighth, the numbers of 
patients available in some analyses was quite small. Despite this, clinically and statistically significant 
differences between the groups were observed. Ninth, while relatively few patients contribute to 
the final periods of follow-up in Figures 2-4, the groups universally diverge long before this and the 
statistics are heavily weighted towards the left of each figure. Tenth, while death due to non-MS 
causes may represent a competing risk, we were unable to include this in the presented models due 
to incomplete reporting. Eleventh, this study did not assess the risks associated with DMTs, and so 
the association between initial F|A|N use and lower risk of SPMS conversion – which is consistent 
with these therapies’ greater effect on relapse rates and disability metrics4,5,26 - must be considered 
in light of their greater risks, administration and monitoring schedules, and initial costs during the 
DMT selection process. 
 
Conclusions 
Among patients with RRMS, initial treatment with fingolimod, natalizumab or alemtuzumab was 
associated with a lower risk of conversion to SPMS compared to initial treatment with ß-IFN|GA over 
a median 5.8 years of follow-up.  These findings, considered along with these therapies’ risks, may 
help inform decisions about DMT selection.  
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Legends for tables and figures 
Table 1: Baseline and follow-up characteristics of matched patient groups. aDisease duration at the 
time of commencing ß-interferon or glatiramer acetate (ß-IFN|GA) in the late group was 6.8 (5.7-
10.8) years [median (IQR)]. bDisease duration at the time of commencing fingolimod or 
alemtuzumab or natalizumab (F|A|N) in the late group was 7.3 (6.1—10.4) years [median (IQR)]. 
EDSS = Expanded Disability Status Scale, range 0 (no disability due to MS) to 10 (death due to MS). 
EDSS 2 indicates minimal disability in one (of eight) functional systems (but no impairment to 
walking). EDSS 3.5 indicates moderate disability in one functional system plus minimal disability in 
several others (but no impairment to walking). IQR = interquartile range. SD = standard deviation. 
Standardized difference quantified by Cohen’s D. 
 
Figure 1: Study design (DMT = disease modifying therapy; EDSS = Expanded Disability Status Scale); 
RCT = randomised controlled trial; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary 
progressive multiple sclerosis; *Where recorded, reasons for stopping were as follows: 341 due to 
intolerance, 65 due to inconvenience, 42 due to pregnancy (or planned pregnancy), 65 due to 
inefficacy (relapses, EDSS progression, MRI activity or patient perception of lack of improvement) 
and 15 due to non-compliance. **Ineligible treatments were defined as treatments not licensed for 
RRMS at the time of the study period (mitoxantrone, cladribine, rituximab, ocrelizumab, siponimod 
or autologous stem-cell transplantation). 
 
Figure 2: Comparison of the cumulative hazard of conversion to secondary progressive multiple 
sclerosis (SPMS) in untreated patients versus matched patients treated with (A) ß-interferon or 
glatiramer acetate (ß-IFN|GA), median (interquartile range (IQR)) follow-up 7.6 (5.8 – 9.6) years; 
(B) fingolimod, (median (IQR) follow-up 4.5 (4.3 – 5.1) years; (C) natalizumab, median (IQR) follow-
up 4.9 (4.4 – 5.8) years; (D) alemtuzumab, median (IQR) follow-up 7.4 (6 – 8.6) years. HR = hazard 
ratio. CI = confidence interval. 
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Figure 3: Comparison of the cumulative hazard of conversion to secondary progressive multiple 
sclerosis (SPMS) in (A) patients treated with ß-interferon or glatiramer acetate (ß-IFN|GA) within 5 
years of disease onset vs matched patients treated with ß-IFN|GA after 5 years of disease onset, 
median (interquartile range (IQR)) follow-up 13.4 (11 – 18.1) years; (B) patients treated with ß-
IFN|GA within 5 years of disease onset vs matched untreated patients, median (IQR) follow-up 7.5 
(5.7 – 9.8) years; (C) patients treated with ß-IFN|GA 5-10 years after disease onset vs matched 
untreated patients, median (IQR) follow-up 7.7 (5.8 – 9.7) years; (D) patients escalated from ß-
IFN|GA to fingolimod or alemtuzumab or natalizumab (F|A|N) within 5 years of disease onset vs 
patients escalated to the same therapy after more than 5 years, median (IQR) follow-up 5.3 (4.6 – 
6.4) years. HR = hazard ratio. CI = confidence interval. 
 
Figure 4: Comparison of cumulative hazard of conversion to secondary progressive multiple 
sclerosis (SPMS) in patients initially treated with fingolimod or alemtuzumab or natalizumab 
(F|A|N) vs matched patients initially treated with ß-interferon or glatiramer acetate (ß-IFN|GA), 
median (interquartile range) follow-up 5.8 (4.7 – 8) years. HR = hazard ratio. CI = confidence 
interval.
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   Mean (SD) 
35 (8) 35 (8) 0 39 (12) 39 (10) 0 39 (9) 38 (9) 0.03 35 (8) 35 (7) 0.08 30 (7) 31 (7) 0.14 
Sex,  
Female, Number (%) 











































Disease duration, years 
   Median (IQR) 
5.7 
(3.1 - 10.5) 
5.1 
(2 - 9.8) 
0.05 4.9 
(1.7 - 9.7) 
5.1 
(2.1 - 9) 
0.03 6.2 
(2 - 10.5) 
5.2 
(2.3 - 8.9) 
0.15 3.2 
(2 - 5.8) 
3.8 
(1.9 - 6.7) 
0.17 3.2 
(2.1 - 4.1) 
3.5 
(2.7 - 4.2)a 
0.26 
Relapses in year before 
baseline 
   Mean (SD)    
1.1 (1) 1.1 (0.9) 0 0.9 (0.9) 0.9 (1) 0.02 1.1 (1) 1.1 (1) 0.01 1.3 (1) 1.3 (1) 0.03 1.0 (1.1) 1.0 (0.9) 0 
Disability, EDSS step 
   Median (IQR) 
2.5 
(1.5 - 3.5) 
2 
(1 - 3.5) 
0.1 2 
(1 - 3.5) 
2 
(1.5 - 3.5) 
0 2.5 
(2 - 4.5) 
3 
(2 - 4.5) 
0.28 3.5 
(2 - 4.5) 
3.5 
(2 - 5.5) 
0 2 
(1.5 - 3) 
2 
(1 – 2.5) 
0 
Baseline year of inclusion 






















Length of setwise-censored 
follow-up, years 
   Median (IQR) 
7.6 
(5.8 - 9.6) 
7.6 
(5.8 - 9.6) 
0 4.5 
(4.3 - 5.1) 
4.5 
(4.3 - 5.1) 
0 4.9 
(4.4 - 5.8) 
4.9 
(4.4 - 5.8) 
0 7.4 
(6 - 8.6) 
7.4 
(6 - 8.6) 
0 13.4 
(11 - 18.1) 
13.4 
(11 - 18.1) 
0 
EDSS frequency during follow 
up, per year 
   Median (IQR) 
2 
(1 – 3.2) 
1 
(0.7 - 1.5) 
0.75 1.6 
(1.1 - 2.6) 
1 
(0.7 - 1.5) 
0.58 1.9 
(1.3 - 2.9) 
1.2 
(0.7 - 1.8) 
0.55 1.1 
(0.9 - 1.5) 
1.2 
(0.9 - 1.9) 
0.11 1.8 
(1.1 - 2.6) 
1.4 
(0.9 - 2.1) 
0.41 
Proportion of time on therapy 
before censor or SPMS 
   Median (IQR) 
1 
(0.9 - 1) 
N/A N/A 1 
(1 - 1) 
N/A N/A 1 
(1 - 1) 
N/A N/A 0.8 
(0.6 - 1) 
N/A N/A 1 
(0.8 - 1) 
0.6 
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   Mean (SD) 
33 (8) 33 (7) 0.02 37 (7) 36 (8) 0.08 33 (9) 32 (8) 0.03 34 (11) 34 (9) 0.06 
Sex,  
Female, Number (%) 

































 Disease duration, years 
   Median (IQR) 
3 
(2.1 - 4) 
2.1 
(1 - 3.5) 
0.5 6.8 
(5.9 - 8.3) 
5.3 
(2.1 - 10) 
0.31 3  
(2.1 - 4) 
3.5  
(2.5 - 4.3)b 
0.41 6.5 
(2.1 - 12) 
5.1 
(2.7 - 9.6) 
0.2 
Relapses in year before 
baseline 
   Mean (SD)    
1.3 (1) 1.2 (1) 0.06 1.1 (1) 0.9 (0.9) 0.18   1 (1.1)  1 (1)  0 1.2 (1.1) 1.3 (1.1) 0.1 
Disability, EDSS step 
   Median (IQR) 
2 
(1 - 3) 
2 
(1 - 3) 
0 2.5 
(1.5 - 3.5) 
2.5 
(1.5 - 3.5) 
0 2  
(1.5 - 3.5) 
2 
(1.1 - 3.0) 
0 2 
(1.5 - 3) 
2 
(1.5 - 3.5) 
0.02 
Baseline year of inclusion 
   Median (IQR) 

















1996   
(1996-7) 
N/A 
Length of setwise-censored 
follow-up, years 
   Median (IQR) 
7.5 
(5.7 - 9.8) 
7.5 
(5.7 - 9.8) 
0 7.7 
(5.8 - 9.7) 
7.7 
(5.8 - 9.7) 
0 5.3  
(4.6 - 6.4) 
5.3 
(4.6 - 6.4) 
0 5.8 
(4.7 - 8) 
5.8 
(4.7 - 8) 
0 
EDSS frequency during follow 
up, per year 
   Median (IQR) 
2.4 
(1.3 - 3.3) 
1 
(0.8 - 1.4) 
1.37 1.7 
(0.8 - 2.9) 
1 
(0.7 - 1.4) 
0.61 2.3 
(1.5 - 3.4) 
 
2 
(1.3 - 3.3) 
 
0.17 1.8 







Proportion of time on therapy 
before censor or SPMS 
   Median (IQR) 
1 
(0.6 - 1) 
N/A N/A 1 
(0.9 - 1) 
N/A N/A 1(0.9 - 1) 0.9 
(0.7 - 1) 
0.54 1 
(1 - 1) 
1 
(0.9 - 1) 
0 
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